These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from Dec. 25 through Dec. 31, 2025. Source: VerityData
Original Filings
Torm $(TRMD)$ Hafnia disclosed a new position in the shipping company of 14,156,061 shares. Hafnia purchased those shares on Dec. 22 pursuant to a Sale and Purchase Agreement with OCM Njord at a price of $22 per share. Hafnia expressed its belief that consolidation is positive for the tanker industry and revealed that it is evaluating strategic opportunities involving its investment, including options for a potential business combination. Following the latest purchase, Hafnia owns an initial 14% stake in Torm's outstanding stock. Shares of Torm lost about 3.4% of their value in 2025.
Increases in Holdings
Vor Biopharma (VOR) ForGrowth III filed an initial 13D regarding its stake in the clinical-stage cell therapy company, shifting to the stance of an activist investor. ForGrowth reported that it purchased 3,237,742 Vor shares through a private placement that closed on Dec. 18 at $10.81 per share. Following the latest purchases, ForGrowth continues to own 10,237,714 Vor shares, or 9.99% of those outstanding, bringing it right up to the established 9.99% beneficial ownership limit. Shares of Vor lost roughly 33.5% of their value in 2025.
Decreases in Holdings
Camp4 Therapeutics $(CAMP)$ Enavate Sciences lowered its stake in the clinical-stage biopharmaceutical company to 3,127,360 shares. Enavate Sciences did so through the sale of 658,442 Camp4 shares from Dec. 16 through Dec. 23 at per share prices ranging from $6.05 to $7.20. Following the latest sales, Enavate Sciences continues to own 6% of Camp4 Therapeutics' outstanding stock. Shares of Camp4 Therapeutics gained about 21.3% in value in 2025.
Recursion Pharmaceuticals (RXRX) Mubadala Investment lowered its stake in the clinical-stage biotechnology company to 9,644,033 shares. Mubadala did so through the sale of 12,985,927 Recursion Pharmaceuticals shares from Dec. 18 through Dec. 23 at per share prices ranging from $4.18 to $4.96. Following the latest sales, Mubadala continues to own 1.9% of Recursion Pharmaceuticals' outstanding stock, placing Mubadala below the 5% threshold that would require it to report further sales. Shares of Recursion lost roughly 42.4% of their value in 2025.
Getty Images Holdings (GETY) Neuberger Berman reduced its stake in the digital image marketplace operator to 55,213,295 shares. Neuberger Berman did so through the open market sale of 3,470,917 Getty Images shares on Oct. 31 at per share prices ranging from $1.97 to $2.75, as well as a pro rata in-kind distribution of 15,428,050 shares to limited partners on Dec. 17. Following the latest activity, Neuberger continues to own 13.3% of Getty Images Holdings' outstanding stock. Shares of Getty Images lost roughly 42.4% of their value in 2025.
Email: editors@barrons.com
This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
January 02, 2026 15:22 ET (20:22 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.